{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.52","value":"4.5"},{"groupId":"OG001","spread":"12.93","value":"5.3"},{"groupId":"OG002","spread":"10.05","value":"4.1"},{"groupId":"OG003","spread":"12.43","value":"6.5"},{"groupId":"OG004","spread":"12.04","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"120"},{"groupId":"OG003","value":"120"},{"groupId":"OG004","value":"118"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.88","value":"4.7"},{"groupId":"OG001","spread":"12.26","value":"5.8"},{"groupId":"OG002","spread":"10.72","value":"4.0"},{"groupId":"OG003","spread":"14.44","value":"7.2"},{"groupId":"OG004","spread":"10.70","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"118"},{"groupId":"OG003","value":"118"},{"groupId":"OG004","value":"117"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.14","value":"4.6"},{"groupId":"OG001","spread":"13.00","value":"5.4"},{"groupId":"OG002","spread":"11.02","value":"4.3"},{"groupId":"OG003","spread":"15.33","value":"7.0"},{"groupId":"OG004","spread":"10.69","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"109"},{"groupId":"OG003","value":"110"},{"groupId":"OG004","value":"108"}],"units":"Participants"}],"title":"Week 36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"123"},{"groupId":"OG003","value":"123"},{"groupId":"OG004","value":"123"}],"units":"Participants"}],"description":"Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.","dispersionType":"Standard Deviation","groups":[{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG000","title":"Pasireotide LAR Overall - AcroQOL Total Scores"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG001","title":"Pasireotide LAR Overall - AcroQOL Physical Sub-scores"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG002","title":"Pasireotide LAR Overall - AcroQOL Psychological Sub-scores"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG003","title":"Pasireotide LAR Overall - AcroQOL Psycho/Appearance Sub-scores"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG004","title":"Pasireotide LAR Overall-AcroQOL Psycho/Pers Relatns Sub-scores"}],"paramType":"MEAN","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 12, 24 & 36","title":"Core Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}